What’s Stopping Us? Using GnRH Analogs With Stable Hormone Addback in Treatment-Resistant Premenstrual Dysphoric Disorder: Practical Guidelines and Risk-Benefit Analysis for Long-term Therapy

References (87)

1. Pearlstein T, Yonkers KA, Fayyad R, et al. Pretreatment pattern of symptom expression in premenstrual dysphoric disorder. J Affect Disord. 2005;85(3):275–282. PubMed CrossRef
2. Halbreich U, Borenstein J, Pearlstein T, et al. The prevalence, impairment, impact, and burden of premenstrual dysphoric disorder (PMS/PMDD). Psychoneuroendocrinology. 2003;28(suppl 3):1–23. PubMed CrossRef
3. Owens SA, Eisenlohr-Moul T. Suicide risk and the menstrual cycle: a review of candidate RDoC mechanisms. Curr Psychiatry Rep. 2018;20(11):106. PubMed CrossRef
4. Osborn E, Brooks J, O’Brien PMS, et al. Suicidality in women with premenstrual dysphoric disorder: a systematic literature review. Arch Women Ment Health. 2021;24(2):173–184. PubMed CrossRef
5. Eisenlohr-Moul T, Divine M, Schmalenberger K, et al. Prevalence of lifetime self-injurious thoughts and behaviors in a global sample of 599 patients reporting prospectively confirmed diagnosis with premenstrual dysphoric disorder. BMC Psychiatry. 2022;22(1):199. PubMed CrossRef
6. Eisenlohr-Moul TA, Girdler SS, Schmalenberger KM, et al. Toward the reliable diagnosis of DSM-5 premenstrual dysphoric disorder: the Carolina Premenstrual Assessment Scoring System (C-PASS). Am J Psychiatry. 2017;174(1):51–59. PubMed CrossRef
7. Joyce KM, Good KP, Tibbo P, et al. Addictive behaviors across the menstrual cycle: a systematic review. Arch Women Ment Health. 2021;24(4):529–542. PubMed CrossRef
8. Eisenlohr-Moul TA. Commentary on Joyce et al: studying menstrual cycle effects on behavior requires within-person designs and attention to individual differences in hormone sensitivity. Addiction. 2021;116(10):2759–2760. PubMed CrossRef
9. Endicott J, Nee J, Harrison W. Daily Record of Severity of Problems (DRSP): reliability and validity. Arch Women Ment Health. 2006;9(1):41–49. PubMed CrossRef
10. Stone AB, Pearlstein TB, Brown WA. Fluoxetine in the treatment of premenstrual syndrome. Psychopharmacol Bull. 1990;26(3):331–335. PubMed
11. Stone AB, Pearlstein TB, Brown WA. Fluoxetine in the treatment of late luteal phase dysphoric disorder. J Clin Psychiatry. 1991;52(7):290–293. PubMed
12. Schmidt PJ, Martinez PE, Nieman LK, et al. Premenstrual dysphoric disorder symptoms following ovarian suppression: triggered by change in ovarian steroid levels but not continuous stable levels. Am J Psychiatry. 2017;174(10):980–989. PubMed CrossRef
13. Marjoribanks J, Brown J, O’Brien PMS, et al. Selective serotonin reuptake inhibitors for premenstrual syndrome. Cochrane Database Syst Rev. 2013;2013(6):CD001396. PubMed CrossRef
14. Shehata NAA, Moety GAFA, El Wahed HAA, et al. Does adding fluoxetine to combined oral contraceptives containing drospirenone improve the management of severe premenstrual syndrome? a 6-month randomized double-blind placebo-controlled three-arm trial. Reprod Sci. 2020;27(2):743–750. PubMed CrossRef
15. Freeman EW, Rickels K, Sondheimer SJ, et al. A double-blind trial of oral progesterone, alprazolam, and placebo in treatment of severe premenstrual syndrome. JAMA. 1995;274(1):51–57. PubMed CrossRef
16. Jackson C, Pearson B, Girdler S, et al. Double-blind, placebo-controlled pilot study of adjunctive quetiapine SR in the treatment of PMS/PMDD. Hum Psychopharmacol. 2015;30(6):425–434. PubMed CrossRef
17. Landén M, Eriksson O, Sundblad C, et al. Compounds with affinity for serotonergic receptors in the treatment of premenstrual dysphoria: a comparison of buspirone, nefazodone and placebo. Psychopharmacology (Berl). 2001;155(3):292–298. PubMed CrossRef
18. Halbreich U. Selective serotonin reuptake inhibitors and initial oral contraceptives for the treatment of PMDD: effective but not enough. CNS Spectr. 2008;13(7):566–572. PubMed CrossRef
19. FDA Drug Safety Communication: Ongoing Safety Review of GnRH Agonists and possible increased risk of diabetes and certain cardiovascular diseases. US Food and Drug Administration. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fda-drug-safety-communication-ongoing-safety-review-gnrh-agonists-and-possible-increased-risk. Published online June 28, 2019. Accessed November 28, 2022.
20. Carlini SV, Deligiannidis KM. Evidence-based treatment of premenstrual dysphoric disorder: a concise review. J Clin Psychiatry. 2020;81(2):19ac13071. PubMed CrossRef
21. Wyatt KM, Dimmock PW, Ismail KMK, et al. The effectiveness of GnRHa with and without “add-back” therapy in treating premenstrual syndrome: a meta analysis. BJOG. 2004;111(6):585–593. PubMed CrossRef
22. Schmidt PJ, Nieman LK, Danaceau MA, et al. Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome. N Engl J Med. 1998;338(4):209–216. PubMed CrossRef
23. Pincus SM, Alam S, Rubinow DR, et al. Predicting response to leuprolide of women with premenstrual dysphoric disorder by daily mood rating dynamics. J Psychiatr Res. 2011;45(3):386–394. PubMed CrossRef
24. Popovic J, Geffner ME, Rogol AD, et al. Gonadotropin-releasing hormone analog therapies for children with central precocious puberty in the United States. Front Pediatr. 2022;10:968485. PubMed CrossRef
25. Yonkers KA, Simoni MK. Premenstrual disorders. Am J Obstet Gynecol. 2018;218(1):68–74. PubMed CrossRef
26. Casper RF, Yonkers KA. Treatment of premenstrual syndrome and premenstrual dysphoric disorder. UpToDate. https://www-uptodate-com.proxy.cc.uic.edu/contents/treatment-of-premenstrual-syndrome-and-premenstrual-dysphoric-disorder?search=premenstrual%20dysphoric%20disorder&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1#H7. Accessed April 4, 2021.
27. Management of premenstrual syndrome: green-top guideline no. 48. BJOG. 2017;124(3):e73–e105. PubMed CrossRef
28. Hornstein MD, Surrey ES, Weisberg GW, et al; Lupron Add-Back Study Group. Leuprolide acetate depot and hormonal add-back in endometriosis: a 12-month study. Obstet Gynecol. 1998;91(1):16–24. PubMed CrossRef
29. Shuster LT, Rhodes DJ, Gostout BS, et al. Premature menopause or early menopause: long-term health consequences. Maturitas. 2010;65(2):161–166. PubMed CrossRef
30. Melton LJ 3rd, Khosla S, Malkasian GD, et al. Fracture risk after bilateral oophorectomy in elderly women. J Bone Miner Res. 2003;18(5):900–905. PubMed CrossRef
31. Rivera CM, Grossardt BR, Rhodes DJ, et al. Increased cardiovascular mortality after early bilateral oophorectomy. Menopause. 2009;16(1):15–23. PubMed CrossRef
32. Rocca WA, Bower JH, Maraganore DM, et al. Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause. Neurology. 2007;69(11):1074–1083. PubMed CrossRef
33. Vannuccini S, Clemenza S, Rossi M, et al. Hormonal treatments for endometriosis: the endocrine background. Rev Endocr Metab Disord. 2022;23(3):333–355. PubMed CrossRef
34. Langer RD, Simon JA, Pines A, et al. Menopausal hormone therapy for primary prevention: why the USPSTF is wrong. Menopause. 2017;24(10):1101–1112. PubMed CrossRef
35. The North American Menopause Society. The NAMS 2017 Hormone Therapy Position Statement Advisory Panel. The 2017 hormone therapy position statement of the North American Menopause Society. Menopause. 2017;24(7):728–753. PubMed CrossRef
36. Rocca WA, Grossardt BR, de Andrade M, et al. Survival patterns after oophorectomy in premenopausal women: a population-based cohort study. Lancet Oncol. 2006;7(10):821–828. PubMed CrossRef
37. Bedaiwy MA, Casper RF. Treatment with leuprolide acetate and hormonal add-back for up to 10 years in stage IV endometriosis patients with chronic pelvic pain. Fertil Steril. 2006;86(1):220–222. PubMed CrossRef
38. Franke HR, van de Weijer PH, Pennings TM, et al. Gonadotropin-releasing hormone agonist plus “add-back” hormone replacement therapy for treatment of endometriosis: a prospective, randomized, placebo-controlled, double-blind trial. Fertil Steril. 2000;74(3):534–539. PubMed CrossRef
39. Di Carlo C, Palomba S, Tommaselli GA, et al. Use of leuprolide acetate plus tibolone in the treatment of severe premenstrual syndrome. Fertil Steril. 2001;75(2):380–384. PubMed CrossRef
40. Howell R, Edmonds DK, Dowsett M, et al. Gonadotropin-releasing hormone analogue (goserelin) plus hormone replacement therapy for the treatment of endometriosis: a randomized controlled trial. Fertil Steril. 1995;64(3):474–481. PubMed CrossRef
41. Surrey ES, Judd HL. Reduction of vasomotor symptoms and bone mineral density loss with combined norethindrone and long-acting gonadotropin-releasing hormone agonist therapy of symptomatic endometriosis: a prospective randomized trial. J Clin Endocrinol Metab. 1992;75(2):558–563. PubMed CrossRef
42. DiVasta AD, Feldman HA, Sadler Gallagher J, et al. Hormonal add-back therapy for females treated with gonadotropin-releasing hormone agonist for endometriosis: a randomized controlled trial. Obstet Gynecol. 2015;126(3):617–627. PubMed CrossRef
43. Mitwally MFM, Gotlieb L, Casper RF. Prevention of bone loss and hypoestrogenic symptoms by estrogen and interrupted progestogen add-back in long-term GnRH-agonist down-regulated patients with endometriosis and premenstrual syndrome. Menopause. 2002;9(4):236–241. PubMed CrossRef
44. Allison MA, Manson JE, Langer RD, et al; Women’s Health Initiative and Women’s Health Initiative Coronary Artery Calcium Study Investigators. Oophorectomy, hormone therapy, and subclinical coronary artery disease in women with hysterectomy: the Women’s Health Initiative Coronary Artery Calcium Study. Menopause. 2008;15(4 Pt 1):639–647. PubMed CrossRef
45. Ingelsson E, Lundholm C, Johansson ALV, et al. Hysterectomy and risk of cardiovascular disease: a population-based cohort study. Eur Heart J. 2011;32(6):745–750. PubMed CrossRef
46. Atsma F, Bartelink MLEL, Grobbee DE, et al. Postmenopausal status and early menopause as independent risk factors for cardiovascular disease: a meta-analysis. Menopause. 2006;13(2):265–279. PubMed CrossRef
47. Salpeter SR, Cheng J, Thabane L, et al. Bayesian meta-analysis of hormone therapy and mortality in younger postmenopausal women. Am J Med. 2009;122(11):1016–1022.e1. PubMed CrossRef
48. Bove R, Secor E, Chibnik LB, et al. Age at surgical menopause influences cognitive decline and Alzheimer pathology in older women. Neurology. 2014;82(3):222–229. PubMed CrossRef
49. Rocca WA, Grossardt BR, Shuster LT. Oophorectomy, estrogen, and dementia: a 2014 update. Mol Cell Endocrinol. 2014;389(1–2):7–12. PubMed CrossRef
50. Kanis JA, Borgstrom F, De Laet C, et al. Assessment of fracture risk. Osteoporos Int. 2005;16(6):581–589. PubMed CrossRef
51. Committee on Practice Bulletins-Gynecology, The American College of Obstetricians and Gynecologists. Practice Bulletin N 129: osteoporosis. Obstet Gynecol. 2012;120(3):718–734. PubMed CrossRef
52. Jeremiah MP, Unwin BK, Greenawald MH, et al. Diagnosis and management of osteoporosis. Am Fam Physician. 2015;92(4):261–268. PubMed
53. Howe TE, Shea B, Dawson LJ, et al. Exercise for preventing and treating osteoporosis in postmenopausal women. Cochrane Database Syst Rev. 2011;(7):CD000333. PubMed CrossRef
54. Jackson RD, LaCroix AZ, Gass M, et al; Women’s Health Initiative Investigators. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med. 2006;354(7):669–683. PubMed CrossRef
55. Dawson-Hughes B, Dallal GE, Krall EA, et al. A controlled trial of the effect of calcium supplementation on bone density in postmenopausal women. N Engl J Med. 1990;323(13):878–883. PubMed CrossRef
56. Reid IR, Ames RW, Evans MC, et al. Effect of calcium supplementation on bone loss in postmenopausal women. N Engl J Med. 1993;328(7):460–464. PubMed CrossRef
57. Garnick MB, Pratt CM, Campion M, et al. The effect of hormonal therapy for prostate cancer on the electrocardiographic QT interval: phase 3 results following treatment with leuprolide and goserelin, alone or with bicalutamide, and the GnRH antagonist abarelix. J Clin Oncol. 2004;22(suppl):4578. CrossRef
58. Levine GN, D’Amico AV, Berger P, et al; American Heart Association Council on Clinical Cardiology and Council on Epidemiology and Prevention, the American Cancer Society, and the American Urological Association. Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. CA Cancer J Clin. 2010;60(3):194–201. PubMed CrossRef
59. Gatti J, Brinker A, Avigan M. Spontaneous reports of seizure in association with leuprolide (Lupron depot), goserelin (Zoladex implant), and naferelin (Synarel nasal spray). Obstet Gynecol. 2013;121(5):1107. PubMed CrossRef
60. Saylor PJ, Keating NL, Freedland SJ, et al. Gonadotropin-releasing hormone agonists and the risks of type 2 diabetes and cardiovascular disease in men with prostate cancer. Drugs. 2011;71(3):255–261. PubMed CrossRef
61. Practice Committee of the American Society for Reproductive Medicine. Combined hormonal contraception and the risk of venous thromboembolism: a guideline. Fertil Steril. 2017;107(1):43–51. PubMed CrossRef
62. Reddy N, Desai MN, Schoenbrunner A, et al. The complex relationship between estrogen and migraines: a scoping review. Syst Rev. 2021;10(1):72. PubMed CrossRef
63. Zürcher A, Knabben L, Janka H, et al. Influence of the levonorgestrel-releasing intrauterine system on the risk of breast cancer: a systematic review. Arch Gynecol Obstet. 2023;307(6):1747–1761. Published online June 18, 2022. PubMed CrossRef
64. Poorolajal J, Heidarimoghis F, Karami M, et al. Factors for the primary prevention of breast cancer: a meta-analysis of prospective cohort studies. J Res Health Sci. 2021;21(3):e00520. PubMed CrossRef
65. Kurebayashi J, Shiba E, Toyama T, et al. A follow-up study of a randomized controlled study evaluating safety and efficacy of leuprorelin acetate every-3-month depot for 2 versus 3 or more years with tamoxifen for 5 years as adjuvant treatment in premenopausal patients with endocrine-responsive breast cancer. Breast Cancer. 2021;28(3):684–697. PubMed CrossRef
66. Zupi E, Marconi D, Sbracia M, et al. Add-back therapy in the treatment of endometriosis-associated pain. Fertil Steril. 2004;82(5):1303–1308. PubMed CrossRef
67. Pang SC, Greendale GA, Cedars MI, et al. Long-term effects of transdermal estradiol with and without medroxyprogesterone acetate. Fertil Steril. 1993;59(1):76–82. PubMed CrossRef
68. Chetkowski RJ, Meldrum DR, Steingold KA, et al. Biologic effects of transdermal estradiol. N Engl J Med. 1986;314(25):1615–1620. PubMed CrossRef
69. Walsh BW, Schiff I, Rosner B, et al. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med. 1991;325(17):1196–1204. PubMed CrossRef
70. Canonico M, Oger E, Plu-Bureau G, et al; Estrogen and Thromboembolism Risk (ESTHER) Study Group. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation. 2007;115(7):840–845. PubMed CrossRef
71. North American Menopause Society. The 2012 hormone therapy position statement of: the North American Menopause Society. Menopause. 2012;19(3):257–271. PubMed CrossRef
72. Santen RJ, Allred DC, Ardoin SP, et al; Endocrine Society. Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab. 2010;95(suppl 1):s1–s66. PubMed CrossRef
73. Shifren JL, Schiff I. Role of hormone therapy in the management of menopause. Obstet Gynecol. 2010;115(4):839–855. PubMed CrossRef
74. Miller VT, LaRosa J, Barnabei V, et al; The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA. 1995;273(3):199–208. PubMed CrossRef
75. Gillet JY, Andre G, Faguer B, et al. Induction of amenorrhea during hormone replacement therapy: optimal micronized progesterone dose. A multicenter study. Maturitas. 1994;19(2):103–115. PubMed CrossRef
76. Hargrove JT, Maxson WS, Wentz AC, et al. Menopausal hormone replacement therapy with continuous daily oral micronized estradiol and progesterone. Obstet Gynecol. 1989;73(4):606–612. PubMed
77. Moorjani S, Dupont A, Labrie F, et al. Changes in plasma lipoprotein and apolipoprotein composition in relation to oral versus percutaneous administration of estrogen alone or in cyclic association with utrogestan in menopausal women. J Clin Endocrinol Metab. 1991;73(2):373–379. PubMed CrossRef
78. Wan YL, Holland C. The efficacy of levonorgestrel intrauterine systems for endometrial protection: a systematic review. Climacteric. 2011;14(6):622–632. PubMed CrossRef
79. Somboonporn W, Panna S, Temtanakitpaisan T, et al. Effects of the levonorgestrel-releasing intrauterine system plus estrogen therapy in perimenopausal and postmenopausal women: systematic review and meta-analysis. Menopause. 2011;18(10):1060–1066. PubMed CrossRef
80. Fraser IS. Non-contraceptive health benefits of intrauterine hormonal systems. Contraception. 2010;82(5):396–403. PubMed CrossRef
81. Bednarek PH, Jensen JT. Safety, efficacy and patient acceptability of the contraceptive and non-contraceptive uses of the LNG-IUS. Int J Womens Health. 2010;1:45–58. PubMed CrossRef
82. Saint Mary’s Hospital Gynecology Services. GnRH Analogue Injections. NHS Manchester University. https://mft.nhs.uk/app/uploads/sites/4/2019/11/19-71-GnRH-analogue-injections-Nov-19.pdf. Published online November 2019.
83. Maguire K, Joslin-Roher S, Westhoff CL, et al. IUDs at 1 year: predictors of early discontinuation. Contraception. 2015;92(6):575–577. PubMed CrossRef
84. Van Poppel H, Abrahamsson PA. Considerations for the use of gonadotropin-releasing hormone agonists and antagonists in patients with prostate cancer. Int J Urol. 2020;27(10):830–837. PubMed CrossRef
85. Dellapasqua S, Gray KP, Munzone E, et al; International Breast Cancer Study Group. Neoadjuvant degarelix versus triptorelin in premenopausal patients who receive letrozole for locally advanced endocrine-responsive breast cancer: a randomized phase II trial. J Clin Oncol. 2019;37(5):386–395. PubMed CrossRef
86. Lambrinoudaki I, Paschou SA, Lumsden MA, et al. Premature ovarian insufficiency: a toolkit for the primary care physician. Maturitas. 2021;147:53–63. PubMed CrossRef
87. Comasco E, Kopp Kallner H, Bixo M, et al. Ulipristal acetate for treatment of premenstrual dysphoric disorder: a proof-of-concept randomized controlled trial. Am J Psychiatry. 2021;178(3):256–265. PubMed CrossRef